Fibromyalgia is a complex widespread pain disorder. OBJECTIVES To evaluate the effectiveness of oral magnesium supplementation in reducing symptom severity among fibromyalgia patients who have not responded to standard treatment, using validated scoring systems such as the Fibromyalgia Impact Questionnaire Revised (FIQR).
Patients diagnosed with FM according to the American College of Rheumatology (ACR) 2016 criteria
Age: 18-65 years.
Not responding to conventional treatment (e.g., amitriptyline, duloxetine, pregabalin) for at least 8 weeks
Patients giving informed consent for enrollment in the study.
1- Patients with renal impairment 2- Pregnant or lactating women 3- Already on magnesium or other mineral supplements 4- Known cases of inflammatory arthritis or other chronic pain syndromes
Parallel
Magnesium glycinate
Dietary supplementFibromyalgia patients who have shown no improvement after at least two months of single standard therapy (amitriptyline, duloxetine, pregabalin) will be recruited from rheumatology clinics. Half participant randomly will be assigned to receive oral magnesium glycinate 850 mg once daily at night for 24 weeks.
Vitamins
Dietary supplementFibromyalgia patients who have shown no improvement after at least two months of single standard therapy (amitriptyline, duloxetine, pregabalin) will be recruited from rheumatology clinics. Half participant will be randomly assigned to receive oral placebo (vitamin supplement) daily for 24 weeks.
Revised Fibromyalgia Impact Questionnaire (FIQR)
Changes in FIQR total score higher scores \>59 means severe disease and low scores\<39 means remission
Changes in FIQR subdomains
changes in individual FIQ sub domains (function, overall impact and symptoms) low score means improvement high scores severe disease
Click on the lead sponsor to view all of their trials.
